Skip to main content

Chembio Diagnostics, Perseus Science Ink Agreement to Advance Point-of-Care Concussion Test

NEW YORK (360Dx) – Chembio Diagnostics said today that it has entered into an agreement with Perseus Science Group to advance the development of a diagnostic test for mild traumatic brain injury, or concussion.

Under the terms of the agreement, Medford, New York-based Chembio will receive funding of an undisclosed amount from Perseus, subject to satisfying certain milestones, to advance the development of a quantitative point-of-care test for concussion that combines Perseus’ concussion biomarker with Chembio's DPP platform, a chromatographic immunoassay.

Chembio said that the agreement builds on previous agreements between the two firms that resulted in the completion of technical feasibility to detect the biomarker patented by Perseus, which is located in Old Lyme, Connecticut.

Financial and other terms of the agreement were not disclosed.

Current methods for diagnosing TBI include neurological examination, cognitive testing, and imaging tests such as CT scan, MRI, and PET scans. Rapid diagnosis of concussion using a point-of-care test could lead to earlier intervention and reduced incidence of secondary injuries, Chembio said.

The DPP platform provides results in about 15 minutes from a drop of fingertip blood.